Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
PharmaCielo Ltd. is a Canada-based life sciences company focused on the cultivation, extraction, processing, and commercialization of pharmaceutical-grade cannabis-derived products, primarily cannabidiol (CBD). The company operates within the cannabis, pharmaceutical ingredients, and health sciences industries, with a business model centered on supplying standardized, GMP-compliant cannabis extracts and active pharmaceutical ingredients (APIs) for medical, wellness, and research applications.
PharmaCielo’s primary revenue drivers have historically included bulk CBD oil and isolate sales, toll-processing services, and intellectual property related to extraction and cultivation methodologies. The company has positioned itself as a low-cost producer through large-scale cultivation in Colombia, leveraging favorable climate conditions and labor economics. Founded in 2015, PharmaCielo evolved from a vertically integrated cannabis cultivator into a company emphasizing pharmaceutical standards and regulatory compliance, though its commercial scale and consistency have fluctuated over time.
Business Operations
PharmaCielo conducts operations primarily through its Colombian subsidiaries, most notably PharmaCielo Colombia Holdings S.A.S., which manages cultivation, extraction, and processing activities. The company controls licensed outdoor cannabis cultivation assets, extraction facilities, and proprietary purification technologies designed to meet international pharmaceutical and food-grade standards. Revenue generation has been driven by the sale of CBD extracts, isolates, and related services to domestic and international customers.
Operations have included both domestic activities in Canada—focused on corporate management, intellectual property, and regulatory strategy—and international operations in Colombia, where agricultural and processing assets are located. The company has also reported partnerships and commercial relationships with distributors and formulation partners in Latin America and other international markets, although the scale and continuity of these arrangements have varied based on regulatory developments and market conditions.
Strategic Position & Investments
PharmaCielo’s strategic direction has emphasized achieving cost leadership in pharmaceutical-grade CBD production and accessing regulated medical and ingredient markets rather than consumer-branded cannabis products. Growth initiatives have included improving operational efficiency, pursuing GMP and equivalent certifications, and targeting bulk ingredient supply agreements with pharmaceutical, nutraceutical, and wellness companies.
The company’s most notable investments have been in its Colombian cultivation and extraction infrastructure and in intellectual property related to processing technologies. PharmaCielo has also held interests in subsidiaries and affiliated entities supporting research, genetics, and international commercialization. Public disclosures indicate ongoing evaluation of emerging applications for cannabinoids in regulated health and therapeutic sectors, though some planned initiatives have faced delays or restructuring, and certain outcomes remain data inconclusive based on available public sources.
Geographic Footprint
PharmaCielo is headquartered in Canada, with its primary operational footprint in Colombia, which serves as the center for cultivation and extraction activities. The Colombian operations provide the company with access to year-round cultivation and export-oriented production capabilities under local cannabis regulations.
Beyond North America and South America, PharmaCielo has reported market engagement and sales efforts targeting Latin America, Europe, and other international jurisdictions where CBD and cannabis-derived ingredients are permitted. While the company has indicated international reach through exports and partnerships, its material operational influence remains concentrated in Colombia and Canada.
Leadership & Governance
PharmaCielo was founded by industry entrepreneurs seeking to apply pharmaceutical standards to cannabis-derived products. The company is governed by a board of directors and led by an executive team responsible for operational execution, regulatory compliance, and strategic repositioning during periods of market volatility. Leadership communications have emphasized regulatory discipline, capital preservation, and a focus on sustainable, compliant operations.
Key executives include:
- Karl Pfotenhauer – Chief Executive Officer
- Douglas Knaul – Chief Financial Officer
- David Attard – Chief Operating Officer
- David Young – Executive Chairman
The leadership team’s stated strategic vision centers on aligning operations with realistic market demand, strengthening governance, and prioritizing pharmaceutical-grade standards over rapid expansion.